MYND Life Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYNDF research report →
About the company
MYND Life Sciences Inc. operates as a neuro-pharmaceutical company, applying life science principles to develop innovative treatments for depressive conditions. The firm conducts scientific research and clinical trials in Canada and the United States, concentrating on therapeutic compounds that possess neuro-anti-inflammatory properties.
- CEO
- Wilfred A. Jefferies
- IPO
- 2021
- HQ
- Kelowna, BC, CA
Price Chart
- Market Cap
- $657.84K
- P/E
- -2.18
- P/S
- 0.00
- P/B
- -0.66
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 35.68%
- ROIC
- 91.43%
- Revenue
- $92.99K · 0.00%
- Net Income
- $-1,517,860 · 57.45%
- EPS
- $-0.03 · 57.98%
- Op Income
- $-1,828,763
- FCF YoY
- 89.10%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.95
- Avg Volume
- 5.22K
Get TickerSpark's AI analysis on MYNDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MYNDF coverage
Recent articles, reports, and earnings notes.
No research on MYNDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MYNDF report →Similar companies
Peers in the same neighborhood.